The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells

Oncogene

Volumn 29, Issue 10, 2010, Pages 1543-1552

  Roidl, A ^a,c   Foo, P ^b,d   Wong, W ^b   Mann, C ^a,e   Bechtold, S ^a,f   Berger, H J ^a,g   Streit, S ^b,h   Ruhe, J E ^b,i   Hart, S ^b,j   Ullrich, A ^a,b   Ho, H K ^b  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^c UNIVERSITY OF MUNICH   (Germany)

^d Sanofi aventis   (Singapore)

^e Eurogentec GmbH   (Germany)

^f Institute for Immunology   (Germany)

^g Research Institute of the Free State of Bavaria   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ U3pharma   (Germany)

^j S BIO Pte Ltd   (Singapore)

more..

Author keywords

Cancer; FGFR4; Mutation; Oncogenesis; Proliferation

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN CELL; MISSENSE MUTATION; MOLECULAR CLONING; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STIMULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; HUMANS; IMMUNOBLOTTING; MICE; MUTATION, MISSENSE; NIH 3T3 CELLS; PHOSPHORYLATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 77949423592     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.432     Document Type: Article

References (35)

1. Ansell A, Farnebo L, Grenman R, Roberg K, Thunell LK. (2009). Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer. Oral Oncol 45: 23-29.
2. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M et al. (2002). Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62: 840-847.
3. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S et al. (2003). Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300: 949.
4. Bignell G, Smith R, Hunter C, Stephens P, Davies H, Greenman C et al. (2006). Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer 45: 42-46.
5. Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA et al. (2001). Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97: 729-736.
6. d'Avis PY, Robertson SC, Meyer AN, Bardwell WM, Webster MK, Donoghue DJ. (1998). Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ 9: 71-78.
7. Dailey L, Ambrosetti D, Mansukhani A, Basilico C. (2005). Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 16: 233-247.
8. Elbashir SM, Harborth J, Weber K, Tuschl T. (2002). Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26: 199-213.
9. Ercolino T, Lombardi A, Becherini L, Piscitelli E, Cantini G, Gagliano MS et al. (2008). The Y606C RET mutation causes a receptor gain of function. Clin Endocrinol (Oxf) 69: 253-258.
10. Eswarakumar VP, Lax I, Schlessinger J. (2005). Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-149.
11. Fishman DA, Liu Y, Ellerbroek SM, Stack MS. (2001). Lysopho-sphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 61: 3194-3199.
12. Giri D, Ropiquet F, Ittmann M. (1999). Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5: 1063-1071.
13. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
14. Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS et al. (2009). Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 50: 118-127.
15. Itoh N, Ornitz DM. (2004). Evolution of the Fgf and Fgfr gene families. Trends Genet 20: 563-569.
16. Koziczak M, Holbro T, Hynes NE. (2004). Blocking of FGFR signaling inhibits breast cancer cell proliferation through down-regulation of D-type cyclins. Oncogene 23: 3501-3508.
17. Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S et al. (2008). Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer 123: 2574-2579.
18. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. (2004). ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6.
19. Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, Ullrich A. (2009). Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 15: 2058-2066.
20. Rousseau F, el Ghouzzi V, Delezoide AL, Legeai-Mallet L, Le MM, Munnich A, Bonaventure J. (1996). Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum Mol Genet 5: 509-512.
21. Ruhe JE, Streit S, Hart S, Wong CH, Specht K, Knyazev P et al. (2007). Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res 67: 11368-11376.
22. Sasaki H, Okuda K, Kawano O, Yukiue H, Yano M, Fujii Y. (2008). Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer. Oncol Rep 20: 1125-1130.
23. Shaoul E, Reich-Slotky R, Berman B, Ron D. (1995). Fibroblast growth factor receptors display both common and distinct signaling pathways. Oncogene 10: 1553-1561.
24. Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C et al. (2005). A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37: 590-592.
25. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J et al. (2004). Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431: 525-526.
26. Streit S, Bange J, Fichtner A, Ihrler S, Issing W, Ullrich A. (2004). Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111: 213-217.
27. Streit S, Mestel DS, Schmidt M, Ullrich A, Berking C. (2006). FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 94: 1879-1886.
28. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM et al. (2007). High-throughput oncogene mutation profiling in human cancer. Nat Genet 39: 347-351.
29. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R et al. (2006). FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 24: 3747-3755.
30. Vargas RA, Maegawa GH, Taucher SC, Leite JC, Sanz P, Cifuentes J et al. (2003). Beare-Stevenson syndrome: two South American patients with FGFR2 analysis. Am J Med Genet A 121A: 41-46.
31. Wang J, Yu W, Cai Y, Ren C, Ittmann MM. (2008). Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 10: 847-856.
32. Weinstein IB. (2002). Cancer. Addiction to oncogenes\the Achilles heal of cancer. Science 297: 63-64.
33. White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S et al. (2005). Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76: 361-367.
34. Wilkie AO. (2005). Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 16: 187-203.
35. Yamaguchi F, Saya H, Bruner JM, Morrison RS. (1994). Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 91: 484-488.